Abstract: The present invention relates to compositions comprising a metal, a metal aggregation inhibitor, and a colour changing agent. The metal is bindable to the colour changing agent to provide a change in colour on binding and/or release thereof.

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

Abstract: Methods for treatment of systemic lupus erythematosus (SLE” or “Lupus”) by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the following general structure and wherein X and Y are as defined herein.

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

Abstract: The present invention relates to compositions comprising a metal, a metal aggregation inhibitor, and a colour changing agent. The metal is bindable to the colour changing agent to provide a change in colour on binding and/or release thereof.

Abstract: Methods for treatment of systemic lupus erythematosus (SLE” or “Lupus”) by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the following general structure and wherein X and Y are as defined herein.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the S1P receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatment of a malcondition for which activation of S1P1 is medically indicated, such as multiple sclerosis.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: Methods and systems for validating positions reported in AIS message signals by fitting suitably chosen functions to signal characteristic data, such as timing and Doppler shift data, derived from a plurality of AIS message signals. Ships whose reported positions deviate from the fitted function may be flagged as suspect.

Abstract: Cancer stem cell populations characterized by expression of CD44hi, ABCG2, ?-catenin, CD117, CD133, ALDH, VLA-2, CD166, CD201, IGFR, and/or EGF1R, and methods of isolating and using the same.

Abstract: A method of extracting automatic identification system (AIS) message segments from AIS signals received by a satellite. The method includes: (a) receiving AIS signals from satellite antennas; (b) generating multiple versions of the AIS signals; (c) extracting message segments contained within each of the AIS signals using one or more AIS receivers; (d) sorting the message segments by time; and (e) deleting any duplicate message segments. Multiple versions of the AIS signals may be generated by one or more of the following methods: (i) processing the AIS signals multiple times, each time with different AIS receiver parameter settings; (ii) splitting each signal into multiple signals and filtering each of the multiple signals separately; (iii) receiving multiple AIS signals and combining them with different phases and amplitudes to produce a plurality of combined AIS signals; and (iv) removing extracted message segments from the received AIS signals and reprocessing the modified AIS signals.

Abstract: Methods and systems for validating positions reported in AIS message signals by fitting suitably chosen functions to signal characteristic data, such as timing and Doppler shift data, derived from a plurality of AIS message signals. Ships whose reported positions deviate from the fitted function may be flagged as suspect.

Abstract: Cancer Stem Cell populations characterized by expression of ABCG2 and methods of isolating and using the same are disclosed.

Abstract: Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Abstract: Various embodiments are described herein for a system and method of detecting Automatic Identification System (AIS) signals in space and decoding these signals. In one aspect, a system for performing this function is described which includes a receiver configured to receive the plurality of AIS signals and pre-process the plurality of AIS signals to produce digital input data, and a processing unit configured to process the digital input data to identify one or more candidate AIS message signals based on Doppler offsets associated with the digital input data, determine corresponding Doppler offset estimates and time estimates of the one or more candidate AIS message signals, decode the one or more candidate AIS message signals to obtain corresponding message segments and validate the decoded message segments for proper AIS formatting.